This new ebook is providing new career and workforce trends in the Life Sciences Industry.
Text of Big opportunities, mixed capabilities - Bridging the talent gap in the global Life Sciences Industry
Big opportunities, mixed capabilitiesmark lanfear
Bridging the talent gap in the gloBal life sciences industry
Change in Life Sciences R&D expenditure
Growing and ageing populations around the globe have greatly increased demand for medicine and health products. As a result, the field of life science – which comprises mainly BioPharmaceutical, Device and Consumer Health companies – has become a trillion-dollar global sector.
The largest companies in the sector are headquartered primarily in the United States
(US) and Western Europe. However, life sciences focused companies in emerging
economies, such as China and India, are beginning to grow aggressively. Between
1999 and 2009, US expenditure in life sciences research and development (R&D)
decreased from 38 percent to 31 percent of the global total. Over the same period,
Asia’s share grew from 24 percent to 32 percent.1
At the same time, many of the industry’s largest and well known are feeling the pinch
as blockbuster treatments come off patent, consumer spending dries up, regulatory
burdens rise and workforces age.
Against this backdrop, there is a high level of global competition for the most talented
science, technology, engineering and math (STEM) staff – especially graduates with
highly specialized skills.
1 NIH, ‘Turning Discovery Into Health’, www.nih.gov/about/impact/impact_global.pdf.
Many of the industry’s established giants are hurting as blockbuster drugs come off patent…
The location of those skilled professionals – and indeed the entire life sciences industry
– is also shifting towards the world’s emerging economies.
India produces 1.2 million engineering graduates annually.2 It also boasts a
pharmaceuticals industry with maturing drug development capabilities and a strong
generics market built, in part, on expired patents. China’s life sciences market is
growing fast as well, with strong increases in STEM graduate numbers and a greater
share of life sciences patents.
However, volume doesn’t always equal quality. In particular, life sciences companies
are finding that many of the new graduates entering the workforce require
additional training to be productive to expected levels. There is no substitute for
experience or quick fix when it is not there.
So what lies ahead? In this industry overview, we discuss how international
outsourcing and collaboration will be vitally important for life sciences players. Across
the sector, the most successful players will be those that can strike the best balance
between the strength of the traditional leaders and the dynamism offered by new
markets and professionals.
2 James Howell, ‘More demand for graduates in STEM subjects’, Graduate-Jobs.com, www.graduate-jobs.com/news/12394/More_demand_for_graduates_in_STEM_subjects.
Life sciences companies are finding that many of the new graduates entering the workforce require extensive training.
A global sector in good health
Companies based in the US and Western Europe lead the trillion-dollar global life science sector – but companies that participate in the Bio-Pharmaceutical and consumer health vertical are growing quickly in emerging markets.
The global life sciences sector is already large and growing rapidly. Population growth
is the main factor increasing demand for life sciences products – emerging markets
have emerging middle classes that are demanding access to a suite of healthcare and
consumer products. The world’s population continues to rise rapidly, standing at 7.1
billion in 2013.1 The United Nations Population Fund estimates it will increase to around
8 billion by 2025.2
The next two most important factors are growth in ageing populations and increasing
levels of diet-related health problems, such as diabetes and hypertension.
This demand is expected to increase sharply in coming years. Between 2000 and 2050,
the World Health Organization (WHO) expects the global number of people over 60 to
double from 11 percent to 22 percent of the world’s population.3
1 Current World Population, About.com, December 2013, geography.about.com/od/obtainpopulationdata/a/worldpopulation.htm. 2 United Nations Population Fund, ‘The World at Seven Billion: Top Issues – Fact Sheets’, July 2011, www.unfpa.org/webdav/site/global/
shared/documents/7%20Billion/7B_fact_sheets_en.pdf.3 World Health Organization, ‘Interesting facts about ageing’, March 2012, www.who.int/ageing/about/facts/en/index.html.
/06A globAl sector In good heAlth
The United Nations Population Fund estimates it will increase to around 8 billion by 2025.
The high global instance of diet-related ailments such as cardiovascular disease and
diabetes has led to much greater demand for preventative drugs and medical devices,
as well as mobile health and eHealth services. WHO cites cardiovascular diseases as
the leading global cause of death and anticipates diabetes will be the seventh leading
cause of death come 2030.4, 5
Slower growth in top 10, aggressive growth in emerging economies
The growth of the world’s largest life sciences companies is slowing. The operating
margin for big pharmaceuticals companies in 2013 is forecast at around 20 percent,
down from more than 24 percent between 2003 and 2009.6
The US is by far the world’s largest life sciences market, turning over $396 billion in
2011. China and Germany were next – Germany’s life sciences market was worth
$41.5 billion in 2011, while China’s is predicted to grow to $127 billion by 2015.7
4 World Health Organization, ‘Diabetes fact sheet’, October 2013, www.who.int/mediacentre/factsheets/fs312/en/index.html.5 World Health Organization, ‘Cardiovascular diseases (CVDs) fact sheet’, March 2013, www.who.int/mediacentre/factsheets/fs317/en/.6 Euler Hermes, ‘Does the global pharmaceutical industry need a new business model?’, Paris, France, March 20, 2012, as quoted in
Deloitte Access Economics, 2013 Global life sciences outlook: Optimism tempered by reality in a “new normal”., www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/dttl-lshc-2013-global-life-sciences-sector-report.pdf.
7 Espicom, ‘EIU: Healthcare and Pharmaceuticals Report – China’, as cited in Deloitte Access Economics, 2013 Global life sciences outlook: Optimism tempered by reality in a “new normal”, www2.deloitte.com/content/dam/Deloitte/global/Documents/Life-Sciences-Health-Care/dttl-lshc-2013-global-life-sciences-sector-report.pdf.
/07A globAl sector In good heAlth
The US is by far the world’s largest life sciences market, turning over $396 billion in 2011.
The US also remains the world’s leading grantor of biopharmaceutical patents, but
its global percentage of patents awarded declined from 38 percent to 33 percent
in the last decade. In contrast, China’s share of global patents granted increased
12 percentage points across the decade to 16 percent in 2009, and continues to rise.
China’s life sciences market is showing significant growth. The country’s pharmaceutical
market is already the world’s second largest with 5.6 percent of the global market
share, and its government has also pledged to invest 2 trillion Yuan ($308.5 billion) to
develop its biotechnology industry.8
Russia, India and Brazil also show promise on the global life sciences stage. Russia’s
government has initiated a $428 million mega-grant program to strengthen life
sciences research and modernize the industry.9 Brazil’s pharmaceutical market is
the third-largest in the Americas, after the US and Canada, with a 2011 value of
$25.7 billion.10, 11 The Economist Intelligence Unit forecasts that India’s pharmaceuticals
market will grow 13 percent annually to $29 billion by 2016.12
8 Generics and Biosimilars Initiative, ‘China’s 5-year biotech investment fires clear warning to US’, August 2013, www.gabionline.net/Biosimilars/News/China-s-5-year-biotech-investment-fires-clear-warning-to-US.
9 UNMC, ‘Dr. Kabanov receives ‘mega-grant’ from Russian Government’, UNMC News, Fall 2011, www.unmc.edu/publicrelations/docs/discover/fall2011_news.pdf.
10 Generics and Biosimilars Initiative Online, ‘The pharmaceutical market in Brazil’, December 2011, www.gabionline.net/Generics/General/The-pharmaceutical-market-in-Brazil.
11 Export.gov, ‘Drugs and Pharmaceuticals Overview’, Doing Business in Brazil: 2011 Country Commercial Guide for U.S. Companies, September 2011, export.gov/Brazil/static/CC_BR_DoingBusiness_CCG_PDF_Chap4_DrugsandPharmaceuticals_Latest_eg_br_062844.pdf.
12 ‘Management Discussions: Global Pharma Market’, India Info Line, May 2013, www.indiainfoline.com/Markets/Company/Fundamentals/Management-Discussions/Unichem-Laboratories-Ltd/506690.
/08A globAl sector In good heAlth
China’s pharmaceutical market is already the world’s second largest with 5.6 percent of the global market share.
Staffing complications call for a talent transplant
A shortage of highly skilled workers is increasing competition for talent among top life sciences companies, compounding other industry pressures.
Access to the best and brightest talent is essential for companies looking to stay
competitive in the face of growing global demand for fast-moving and technologically
sophisticated pharmaceuticals and biotechnology products. However, it’s a complex
landscape right now – while some areas of the market are growing quickly and new
talent is becoming available, we are also seeing waves of layoffs among leading
companies as they adjust to new, lower-profit realities.
Operating pressures have resulted in cost cutting and layoffs
Between 2009 and 2012, expired pharmaceutical patents led to an estimated
$100 billion worth of lost drug sales worldwide. This figure is expected to be
$29 billion in 2013 alone.1 Companies that specialize in generic drug manufacturing
are now free to begin the process of producing equivalent therapies for a decreased
cost, which is placing pressure on organizations seeking to fund fresh innovation from
revenues earned from profits on earlier successes.
1 Generics and Biosimilars Initiative Online, ‘The biggest drug patent losses for 2013’, May 2013, www.gabionline.net/Generics/General/The-biggest-drug-patent-losses-for-2013.
/10stAffIng complIcAtIons cAll for A tAlent trAnsplAnt
Companies that specialize in generic drugs can now legally produce much cheaper alternatives to name-brand products.
Many of the world’s leading pharmaceuticals companies have seen significant
staff reductions in the past few years. One of the market’s largest players reported
over $60 billion in revenue in 2012 and a growth in its stock values, but at the cost of
downsizing and losing critical talent for a second year in a row. The challenges of the
over-stressed market and loss of profitabliity is driving very hard decisions.
Asia disrupting recruitment flows
As China’s life sciences industry grows, it is investing heavily in talent. The country’s
universities now produce more life sciences graduates and post-graduates than any
other nation.2 Chinese students are also studying offshore, securing the most American
doctoral degrees in biological sciences after American students.3
Many of these internationally educated and trained professionals are now also
returning home. According to a recent study, at least 80,000 Western-trained
post-graduates with life sciences doctorates returned to China to work in companies
or academic institutes.4
2 Robert. D. Atkinson, Stephen J. Ezell, L. Val Giddings, Luke A. Stewart, and Scott M. Andes, ‘Leadership in Decline – Assessing US International Competitiveness in Biomedical Research’, May 2012, www.unitedformedicalresearch.com/wp-content/uploads/2012/07/Leadership-in-Decline-Assessing-US-International-Competitiveness-in-Biomedical-Research.pdf.
3 NIH, ‘Turning Discovery Into Health’, www.nih.gov/about/impact/impact_global.pdf.4 George Baeder, Michael Zielenziger, ‘The Life Sciences Leader of 2020,’ 2010, wenku.baidu.com/view/0705856d1eb91a37f1115c4c.
/11stAffIng complIcAtIons cAll for A tAlent trAnsplAnt
China’s universities now produce more life sciences graduates and post-graduates than any other nation.
Emerging talent pools need further training
While rising stars such as China and India are producing large numbers of STEM
graduates each year, the caliber of talent is yet to become consistently high enough
to satisfy the needs of the global sector. This is another example of how talent looks on
paper is not wholly indicative of their ability to be successful in a corporation.
This ‘talent gap’ poses a challenge for pharmaceutical companies aiming to send R&D
facilities offshore as needed skillsets and experience are lacking. It also complicates the
process of outsourcing work for biotechnology companies and suggests that many of
the experienced professionals being shed by the industry may still have plenty to offer.
/12stAffIng complIcAtIons cAll for A tAlent trAnsplAnt
The caliber of talent is yet to become consistently high enough to satisfy the needs of the global sector.
Cultivating new talent cultures
Life sciences companies should secure valuable talent by outsourcing and creating partnering arrangements with progressive, like-minded international peers. Companies may also consider extending recruitment age ranges to encompass STEM initiatives in schools and creating flexible work opportunities for highly skilled retired or retiring workers.
Despite layoffs and cost-cutting in various segments of life sciences, the sector is still
growing as a whole worldwide. It also faces a widening skills gap as fewer high-end
graduates find their way into the workforce.
The ongoing shortage of world-class STEM talent requires life sciences companies to
become more resourceful in their recruitment strategies. For example, groups that
previously focused their recruiting on specific academic pockets in Europe and the US
are beginning to turn to top international universities – often in emerging markets – to
find graduate talent. Those seeking more experienced STEM workers are looking to
the fast-growing and progressive biotechnology firms and post-graduate labs around
/14cultIvAtIng new tAlent cultures
Groups that previously focused their recruiting on specific academic pockets in Europe and the US are beginning to turn to top international universities – often in emerging markets.
Helping close the talent gap
Companies seeking STEM workers in emerging countries should explore new ways
of finding and nurturing local talent. Pharmaceutical companies may consider
investing in educational programs and facilities to train promising STEM graduates
to meet world standards. Biotechnology companies could take a similar approach
by attracting promising STEM candidates with scholarships and initiatives through
Both industries could benefit from using low-cost collaborative technologies
(such as video conferencing and cloud-based platforms) to partner with universities
and development firms. These technologies may present life sciences companies
with cost effective ways to ‘test the waters’ overseas, by outsourcing selected
operational and production aspects and forming tentative partnerships with other
/15cultIvAtIng new tAlent cultures
These technologies may present life sciences companies with cost-effective ways to ‘test the waters’ overseas.
A broader recruitment net
BioPharmaceutical, Medical Device, and Consumer Health corporations also need
to consider the issue of retaining enough skilled workers. One way to counter staff
turnover trends is to broaden target recruitment demographics. In addition to seeking
out new sources of talent overseas, pharmaceutical and biotechnology companies
should consider changing recruitment intake to encompass a wider range of ages and
experience levels. Segmenting skillsets and job functions through proactive workforce
planning drive strategic decision making when it comes to talent acquisition and
For example, companies could explore the possibility of creating and funding
educational initiatives for students in high schools and colleges in promising
international life sciences markets. This can help nurture talent pools by providing
students with education opportunities and pathways into sought-after global roles.
At the same time, it gives companies a way to find and educate tomorrow’s
high-end STEM workers, thereby forging a more sustainable stream of quality talent
for future growth.
/16cultIvAtIng new tAlent cultures
One way to counter staff turnover trends is to broaden target recruitment demographics.
Holding on to experienced workers
At the other end of the spectrum, life sciences companies can widen talent pathways
by targeting older, highly experienced STEM workers. While these workers may have
retired or be planning retirement, many are increasingly likely to seek supplemental
income through part-time or reduced-work programs. The opportunity to have
these experienced professionals in your talent mix will raise the knowledge of your
Alternatively, companies could investigate offering reduced-work programs to mature-
aged STEM workers. By combining a percentage of on-shore or core resources
with off-shoring or outsourcing engagements lessens the risk of discontinuity. This
approach saves wage costs and retains experienced staff, while also accommodating
the need for lower working hours among older employees and easing the transition to
retirement for all involved.
Collaborative technologies such as video telephony and cloud computing can
also help to accommodate older workers if they are geographically removed from
the company. Technology should be use extensively, not to replace, but enhance
the human experience in our business. The wealth of experience in this
demographic of the global talent pool could prove invaluable for supporting future
life sciences innovation.
/17cultIvAtIng new tAlent cultures
Companies could investigate offering reduced-work programs to mature-aged STEM workers.
for more thought leadership go to talentproject.com